Accutar Biotech

Accutar Biotech

Drug discovery artificial intelligence company founded in 2015 by Jie Fan and Ke Liu.

Accutar Biotech - also known as AccutarBio - is a company that develops a drug discovery artificial intelligence platform. It was founded in 2015 by Jie Fan, Ke Liu. It is headquartered in Shanghai, China, and maintains an additional office in New York City, United States. The company has received funding from IDG Capital, Yitu Technology, and ZhenFund.

Product and service

Accutar Biotech's AI is made up of several components: Accutar Virtual Screen, Docking, Intelligent-SAR, and Chemi-Net. These integrated components are used to design novel drug compounds and are intended to be used during the drug development and preclinical trial phases. The virtual representation of protein-ligand bindings is conducted through Accular Virtual Screen and Docking. Intelligent-SAR generates novel compounds which are then validated through co-crystallization and binding assays. Its Chemi-Net platform uses a deep neural network to predict absorption, distribution, metabolism, and excretion (ADME) of these compounds.

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

AccutarBio Advances AI in Drug Discovery - SyncedReview - Medium

Synced

Web

May 1, 2018

Chemi-net: a graph convolutional network for accurate drug property prediction

Ke Liu, Xiangyan Sun, Lei Jia, Jun Ma, Haoming Xing, Junqiu Wu, Hua Gao, Yax Sun, Florian Boulnois, Jie Fan

Journal article

March 16, 2018

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.